COGNITION THERAPEUTICS INC Stock Price, News & Analysis

Cognition Therapeutics (NASDAQ: CGTX) announced completion of target enrollment for the randomized, placebo‑controlled Phase 2 START study of zervimesine (CT1812) in mild cognitive impairment and early Alzheimer’s disease, reaching 540 participants.

Approximately 50% of participants were enrolled during the last six months and ~15% of randomized participants were receiving background infusions of Leqembi (lecanemab) or Kisunla (donanemab). Topline results are expected after all participants complete 18 months of treatment.

Cognition Therapeutics (NASDAQ: CGTX) reported Q3 2025 results and program updates on Nov 6, 2025. The company completed a $30.0 million registered direct offering of 14,700,000 shares to fund next‑stage development of zervimesine (CT1812). Cognition said it achieved FDA alignment on a registrational path for zervimesine in Alzheimer’s disease and exceeded 75% enrollment in the Phase 2 START study. An expanded access program for dementia with Lewy bodies continues. Cash and equivalents were about $39.8 million with $36.3 million in remaining NIA grant funds; the company estimates runway into Q2 2027. Q3 net loss was $4.9 million (‑$0.06/share).

Cognition Therapeutics (NASDAQ: CGTX) announced that its Phase 2 'START' Study for zervimesine (CT1812) has achieved 75% enrollment of its target 540 participants with mild cognitive impairment (MCI) and early Alzheimer's disease. The study, conducted in collaboration with the Alzheimer's Clinical Trials Consortium (ACTC) and funded by the National Institute of Aging, will evaluate the drug against placebo over an 18-month treatment period.

The company previously reported positive results from its SHINE Study in 2024, which demonstrated that zervimesine slowed cognitive deterioration in mild-to-moderate Alzheimer's patients with lower p-tau217 levels. The START Study aims to evaluate the drug's efficacy in earlier disease stages.

Cognition Therapeutics (NASDAQ: CGTX) has successfully closed a $30 million registered direct offering through the sale of 14.7 million shares of common stock at $2.05 per share to two new fundamental institutional investors, including a leading global investment firm.

The offering, managed by Titan Partners Group, will support the Phase 3 development of zervimesine (CT1812), the company's drug candidate for treating neurodegenerative disorders. CEO Lisa Ricciardi highlighted that this investment validates their positive data in three major age-related degenerative disorders.

The shares were offered under a previously filed and effective S-3 shelf registration statement, with the prospectus available through the SEC website and Titan Partners Group.

Cognition Therapeutics (NASDAQ: CGTX) has announced a $30 million registered direct offering of common stock, involving the sale of 14,700,000 shares to two new fundamental institutional investors, including a prominent global investment manager.

The offering is expected to close around August 29, 2025, with Titan Partners Group acting as the sole placement agent. The proceeds will fund the preparation of Phase 3 programs for zervimesine in neurodegenerative disorders, along with working capital and general corporate purposes.

Cognition Therapeutics (NASDAQ: CGTX), a clinical-stage company focused on neurodegenerative disorder treatments, has successfully regained compliance with Nasdaq's minimum bid price requirement. The company met Nasdaq's Rule 5550(a)(2) by maintaining a closing bid price of $1.00 or higher for at least 10 consecutive business days, achieving this milestone on August 25, 2025.

Following this achievement, Nasdaq has officially closed the bid price deficiency matter, confirming Cognition's continued listing on the exchange.

Cognition Therapeutics (NASDAQ: CGTX) has received FDA confirmation for its Phase 3 program design for zervimesine (CT1812) in Alzheimer's disease treatment. The FDA agreed that two six-month Phase 3 studies could support a New Drug Application (NDA).

The Phase 3 trials will focus on adults with mild-to-moderate Alzheimer's who have lower p-tau217 levels. Previous Phase 2 "SHINE" study showed that zervimesine achieved a 95% reduction in cognitive decline compared to placebo in this population. The studies will randomize participants to receive either 100mg daily oral zervimesine or placebo, with participants eligible for an open-label extension study upon completion.

Cognition Therapeutics (NASDAQ: CGTX) reported significant progress in its clinical programs for Q2 2025, particularly with its lead drug candidate zervimesine. The company achieved key milestones including surpassing 50% enrollment in Phase 2 'START' study for early Alzheimer's disease, reporting positive topline results in dry AMD with 28.6% reduction in GA lesion growth, and initiating an expanded access program for DLB patients.

Financial results showed cash position of $11.6 million with additional $41.9 million in NIA grant funds. Q2 2025 net loss was $6.7 million ($0.11 per share), improved from $7.0 million loss in Q2 2024. The company expects sufficient funding into Q2 2026.

Cognition Therapeutics (NASDAQ: CGTX) presented significant clinical data for their drug zervimesine (CT1812) at AAIC 2025, demonstrating positive results in both Dementia with Lewy Bodies (DLB) and Alzheimer's disease trials.

In the Phase 2 SHIMMER study, DLB patients treated with zervimesine showed 86% better scores than placebo on neuropsychiatric symptoms. The Phase 2 SHINE study in Alzheimer's revealed that patients with lower p-tau217 levels showed remarkable response, with cognitive deterioration arrested by 129% in mild cases and 91% in moderate cases.

Additional biomarker analyses showed significant reductions in plasma GFAP and promising trends in NfL and amyloid beta species, indicating zervimesine's impact on underlying disease biology.